http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2699508-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_24a7ed8688c3e1018fb8ae5ce0b15151 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N5-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-49 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-401 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-067 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 |
| filingDate | 2018-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d388719bef95601dc49c18c93a3af8d0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a859ab6d58c352d451906401d3d1f7f5 |
| publicationDate | 2019-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2699508-C1 |
| titleOfInvention | Method of treating patients with metabolic syndrome |
| abstract | FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to cardiology, and can be used for treating patients with metabolic syndrome. That is ensured by introducing Metformin 500 mg twice a day, Atorvastatin 10 mg in the evening, Lysinopryl 5 mg 1-2 times a day. It is combined with intravenous laser blood irradiation (ILBI) at wave length 0.405 mcm, output power at trunk light guide end 1–1.5 mWt for 15 minutes in continuous illumination mode. ILBI is differentiated depending on the duration of the disease, level of lipid metabolism, level of leptin and adiponectin concentration in blood serum. If disease duration is less than 3 years, with LDL cholesterol less than 3.5±0.59 mmol/l, HDL cholesterol more than 1.2±0.04 mmol/l, TG less than 1.62±0.16 mmol/l, leptin level equal to or less than 20±0.42 pg/ml, adiponectin level equal to or less than 6±0.45 pg/ml is followed by 7 daily procedures of ILBI. If the disease lasts more than 3 years, with a LDL cholesterol level greater than 3.5±0.59 mmol/l, a cholesterol HDL less than 1.2±0.04 mmol/l, a TG more than 1.62±0.16 mmol/l, leptin level more than 20±0.42 pg/ml, level of adiponectin more than 6±0.45 pg/ml 10 daily procedures are performed.EFFECT: such implementation of the method provides more effective drug-induced treatment, reduced clinical manifestations of metabolic syndrome, reduced drug load on the patient, normalized carbohydrate metabolism, leptin, adiponectin and cytokines.1 cl, 8 tbl, 2 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2734051-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2727465-C1 |
| priorityDate | 2018-07-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 270.